Aurobindo gets FDA approval for dicloxacillin sodium capsules

Print Friendly, PDF & Email

EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application dicloxacillin sodium capsules USP, 250mg and 500mg. Aurobindo Pharma’s dicloxacillin sodium capsules are an AB-rated generic equivalent to the reference listed drug (RLD), Pathocil Capsules, manufactured by Wyeth Ayerst Laboratories.

Dicloxacillin sodium capsules are indicated for the treatment of infections caused by penicillinase-producing staphylococci, which have demonstrated susceptibility to the drug.

Dicloxacillin sodium capsules has an estimated market size of US $5.3 Million for the twelve months ending July 2022, as per IQVIA.


Adheris Health

Comments are closed.

Adheris Health